The Potential for Gene Therapy in Pancreatic Cancer
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 26 (1) , 5-22
- https://doi.org/10.1385/ijgc:26:1:5
Abstract
Pancreatic cancer is highly aggressive and is a leading cause of cancer death in the Western world. Currently, there is no effective treatment for this disease; resection is only available to a small fraction of patients and has a marginal effect on overall survival rates. Chemotherapy and radiation also have very limited effects on patient survival. There is clearly a need for new approaches to treatment of such an aggressive disease. Gene therapy is of potential use in the treatment of cancer, and all currently available strategies are discussed with relevance to pancreatic cancer. A key to such strategy is specific delivery and selective gene expression in target cells. Current approaches include replacement of tumor suppressor genes, the use of antisense (AS) oligonucleotides, gene-directed enzyme prodrug therapy (GDEPT), and immunotherapy. The scene is now set for the next phase of development in clinical trials.Keywords
This publication has 97 references indexed in Scilit:
- Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954Gene Therapy, 1998
- In vivo Adenovirus‐mediated Prodrug Gene Therapy for Carcinoembryonic Antigen‐producing Pancreatic CancerJapanese Journal of Cancer Research, 1998
- A chimeric fusion protein containing transforming growth factor-α mediates gene transfer via binding to the EGF receptorGene Therapy, 1998
- Suppression of Pancreatic Cancer by the Dominant NegativerasMutant, N116YJournal of Surgical Research, 1996
- Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3Carcinogenesis: Integrative Cancer Research, 1996
- Antisense Regulation of Oncogenes in Human CancerCritical Reviews™ in Oncogenesis, 1996
- In VivoAdenovirus-Mediated Gene Transfer of theEscherichia coliCytosine Deaminase Gene to Human Colon Carcinoma-Derived Tumors Induces Chemosensitivity to 5-FluorocytosineHuman Gene Therapy, 1995
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Induction and Expression of Heparin-Binding EGF-Like Growth Factor in Human Pancreatic CancerBiochemical and Biophysical Research Communications, 1994
- Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.Journal of Clinical Investigation, 1992